Skip to main content
OpenTrials
Completed

NCT Number: NCT01912287

GATE: Generalized Anxiety - A Treatment Evaluation

The purpose of this randomized study is to examine the comparative efficacy of yoga, cognitive behavioral therapy, and stress education, a previously employed control condition, for patients with Generalized Anxiety Disorder.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Boston University, Boston, Massachusetts, United States

Loading trial locations.

About this study

We are currently conducting a treatment study to reduce stress and anxiety in people with generalized anxiety disorder (GAD). This study will not use a medication, but instead will involve weekly stress reduction classes that use different strategies to reduce anxiety. The study involves having a formal psychiatric interview, filling out questionnaires, ECGs, saliva samples, a urine test for drugs of abuse, and study visits over 12 weeks. Each study visit will take a few hours. Qualified participants will be compensated for time and travel.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female outpatients > 18 years of age with a primary psychiatric diagnosis of generalized anxiety disorder
  • Clinical Global Impression-Severity scale (CGI-S) score of 4 or higher
  • Off concurrent psychotropic medication for at least 2 weeks prior to initiation of randomized treatment, OR stable on current medication for a minimum of 6 weeks and willing to maintain a stable dose
  • Willingness and ability to perform the yoga intervention and to comply with the requirements of the study protocol.
  • For women of childbearing potential, willingness to use a reliable form of birth control

Exclusion criteria

  • Patients unable to understand study procedures and participate in the informed consent process.
  • Pregnancy as assessed by pregnancy test at screen or lack of use approved methods birth control for women of childbearing age
  • Women who are planning to become pregnant
  • Serious medical illness or instability for which hospitalization may be likely within the next year
  • Significant current suicidal ideation or suicidal behaviors within the past 6 months (assessed with the Beck Depression Inventory-II [BDI-II])
  • History of head trauma causing loss of consciousness, or seizure disorder resulting in ongoing cognitive impairment
  • Posttraumatic stress disorder, substance use disorder, eating disorder, or organic mental disorder within the past 6 months
  • Lifetime history of psychotic disorder, bipolar disorder, or developmental disorder
  • Significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview)
  • Prior experience with (more than 5 Yoga classes or CBT sessions within the last 3 years) and/or current practice of mindbody techniques (e.g., yoga, meditation, Tai-Chi, etc) or cognitive behavioral therapy (CBT)
  • Concomitant therapy for generalized anxiety disorder (GAD) (any therapy)
  • Physical conditions that might cause injury from yoga (pregnancy, physical injuries and musculoskeletal problems)
  • Cognitive impairment (MOCA<21)

Treatment and study plan

Cognitive behavioral therapy

Behavioral

CBT focused on Generalized Anxiety Disorder (12 sessions)

Other names: CBT

Stress Education

Behavioral

Active control group (12 sessions)

Other names: SE

Yoga

Behavioral

12 sessions, mindfulness components

Other names: Kundalini Yoga

Primary outcomes

  1. Proportion of Participants With Treatment Response

    Time frame: Biweekly from weeks 0 through 12

    Treatment response is a dichotomous outcome coded 0=no treatment response, 1= treatment response. This treatment response coding was derived from the Clinical Global Impression-Improvement (CGI-I) measure. The CGI-I is a clinician administered instrument that assesses level of symptom change across the course of treatment. The CGI-I ranges from 1 to 7, with lower scores indicating greater improvement. Our treatment response outcome variable was coded 0 if CGI-I was 3 or more. Treatment response was coded 1 if CGI-I was rated 1 (very much improved) or 2 (much improved).

Secondary outcomes

  1. Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A)

    Time frame: Weeks 0, 6 , 12 and 6 month follow up

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

Registry information

Important dates

Study start
2013
Primary completion
2019
Study completion
2019
First posted
Jul 31, 2013
Registry last updated
Jun 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.